Metabolic Syndrome

Metabolic syndrome (MetS) is a clustering of interrelated cardiometabolic risk factors — central obesity, atherogenic dyslipidaemia, hypertension and dysglycaemia — that together more than double the risk of atherosclerotic cardiovascular disease (ASCVD) and confer a roughly five-fold higher risk of type 2 diabetes mellitus (T2DM). It is also called syndrome X, the insulin resistance syndrome, or Reaven's syndrome (after Gerald Reaven, who in 1988 first linked insulin resistance to the cluster). For NEET PG it is a favourite because of its competing diagnostic criteria, its mechanistic centre (insulin resistance), and its classic vignette overlap with Cushing syndrome.

Definition and the central concept

Metabolic syndrome is not a disease but a diagnostic construct — a defined cluster of risk factors that identifies people at high cardiometabolic risk who benefit from aggressive lifestyle and risk-factor modification. The unifying pathophysiological hypothesis is insulin resistance with compensatory hyperinsulinaemia, occurring on a background of visceral (central) adiposity.

High-yield: The single most important and most consistently required component across modern criteria is central (abdominal/visceral) obesity, measured by waist circumference, not BMI. Visceral fat — not subcutaneous fat — drives the syndrome.

Classification — the competing diagnostic criteria

Several bodies have published criteria. NEET PG most often tests ATP III (NCEP) and IDF, and the difference between them.

NCEP ATP III (2001, revised 2004/2005)

Diagnosis requires any 3 of the following 5 criteria. No single component is mandatory.

Component	ATP III cut-off
Central obesity (waist circumference)	Men > 102 cm; Women > 88 cm
Triglycerides	≥ 150 mg/dL (or on treatment)
HDL cholesterol	Men < 40 mg/dL; Women < 50 mg/dL
Blood pressure	≥ 130/85 mmHg (or on treatment)
Fasting glucose	≥ 100 mg/dL (revised; originally ≥ 110)

IDF (2005)

The IDF makes central obesity mandatory (assessed by ethnicity-specific waist circumference) PLUS any 2 of the remaining 4 factors (TG, HDL, BP, glucose — same cut-offs as ATP III, with fasting glucose ≥ 100 mg/dL).

High-yield: ATP III = any 3 of 5 (waist optional). IDF = central obesity mandatory + any 2 more. This is the single most frequently asked distinction. If a vignette says "abdominal obesity is essential/compulsory," the answer is IDF.

IDF ethnicity-specific waist circumference

The IDF recognised that the ATP III Western cut-offs (102/88 cm) miss high-risk South Asians who develop visceral adiposity at lower waist sizes ("thin–fat Indian" / metabolically obese normal weight phenotype).

Population	Men	Women
Europid / White	≥ 94 cm	≥ 80 cm
South Asian / Chinese	≥ 90 cm	≥ 80 cm
Japanese	≥ 90 cm	≥ 80 cm
US (ATP III default)	≥ 102 cm	≥ 88 cm

High-yield: For Indians and other South Asians, the waist circumference cut-off is ≥ 90 cm in men and ≥ 80 cm in women — lower than the Western thresholds. This is a very common exam point.

Harmonised criteria (2009 Joint Interim Statement)

To resolve the conflict, IDF + AHA/NHLBI + WHF + IAS + IASO issued harmonised criteria: any 3 of 5 (like ATP III, so waist is no longer mandatory) but using population/ethnicity-specific waist cut-offs (like IDF). This is the current consensus standard.

Other historical definitions (lower yield)

• WHO (1999): required insulin resistance (T2DM, IFG, IGT, or low glucose uptake on clamp) as the mandatory anchor, plus 2 others; uniquely included microalbuminuria (urinary albumin ≥ 20 µg/min or ACR ≥ 30 mg/g) and used waist-hip ratio rather than waist circumference.
• EGIR (1999): required hyperinsulinaemia; used waist circumference; excluded diabetics.

High-yield: Microalbuminuria appears only in the WHO definition. Insulin resistance is mandatory only in WHO and EGIR, not in ATP III/IDF/harmonised.

Etiology and pathophysiology

The mechanistic story flows from visceral fat to systemic insulin resistance:

Excess caloric intake + physical inactivity + genetic predisposition → visceral adiposity → dysfunctional, hypertrophied adipocytes → altered adipokines + free fatty acid (FFA) flux → systemic insulin resistance → compensatory hyperinsulinaemia → the full cluster (dysglycaemia, dyslipidaemia, hypertension).

Key mechanistic threads:

1. Free fatty acid overload. Visceral fat is lipolytically active and drains via the portal vein directly to the liver. Excess FFA causes hepatic insulin resistance, increased gluconeogenesis, and increased VLDL production.
2. Adipokine imbalance. ↓ Adiponectin (insulin-sensitising, anti-inflammatory, anti-atherogenic) and ↑ leptin, resistin, TNF-α, IL-6, PAI-1. Low adiponectin is a hallmark.
3. Atherogenic dyslipidaemia. Insulin resistance → ↑ VLDL/triglycerides; cholesteryl ester transfer protein (CETP) exchanges TG for cholesteryl esters, producing low HDL and small, dense LDL particles (highly atherogenic). The classic lipid triad: high TG + low HDL + small dense LDL (the "lipid triad" / atherogenic dyslipidaemia). Note LDL-C may be normal, but particle number/quality is abnormal.
4. Hypertension. Hyperinsulinaemia → renal Na+ retention, sympathetic overactivity, endothelial dysfunction (↓ nitric oxide), and RAAS activation.
5. Pro-inflammatory, pro-thrombotic state. ↑ CRP, ↑ PAI-1 (impaired fibrinolysis) and ↑ fibrinogen contribute to ASCVD risk.
6. Hepatic consequence. Ectopic fat → non-alcoholic fatty liver disease (NAFLD / MAFLD), which can progress to NASH.

High-yield: Low adiponectin and high PAI-1 are the classic biomarker derangements. The atherogenic lipid pattern is high TG, low HDL, and small dense LDL — LDL-C itself can be normal.

Conditions strongly associated with MetS

• PCOS (insulin resistance is central; metformin used).
• NAFLD/NASH (the "hepatic manifestation" of MetS).
• Obstructive sleep apnoea (OSA) — bidirectional relationship.
• Hyperuricaemia / gout.
• Acanthosis nigricans — cutaneous marker of insulin resistance.
• Hypogonadism in men; chronic kidney disease; increased risk of certain cancers (colon, breast, endometrial).

Clinical features

MetS is often asymptomatic and detected on screening. Look for:

• Central obesity — increased waist circumference, "apple-shaped" body.
• Acanthosis nigricans and skin tags (acrochordons) — markers of hyperinsulinaemia.
• Xanthelasma / tendon xanthomas if marked dyslipidaemia.
• Features of associated conditions: hirsutism/oligomenorrhoea (PCOS), daytime somnolence/snoring (OSA), hepatomegaly (NAFLD).
• Often a positive family history of T2DM, premature CAD.

Diagnosis and investigations

Diagnosis is clinical + simple labs against the chosen criteria. There is no single confirmatory test.

Stepwise approach: 1. Measure waist circumference (tape midway between lowest rib and iliac crest, at end of normal expiration) → 2. Office blood pressure → 3. Fasting lipid profile (TG, HDL) → 4. Fasting plasma glucose → 5. Apply criteria (≥3 of 5 for harmonised/ATP III).

Supportive / workup investigations:

• Fasting glucose, HbA1c, OGTT — to characterise dysglycaemia.
• HOMA-IR (= fasting insulin µU/mL × fasting glucose mg/dL ÷ 405) — research/quantification of insulin resistance; > 2.5 suggests resistance. Not part of formal diagnostic criteria.
• LFTs + ultrasound for NAFLD; hs-CRP, uric acid.
• TSH (exclude hypothyroidism as a cause of dyslipidaemia/weight gain).
• If Cushing suspected → overnight 1 mg dexamethasone suppression test / late-night salivary cortisol / 24-h urinary free cortisol.

High-yield: HOMA-IR is NOT a diagnostic criterion for metabolic syndrome under ATP III/IDF — it quantifies insulin resistance but the diagnosis is made by the 5-component clustering.

Management

The cornerstone is therapeutic lifestyle change (TLC) — there is no single "drug for metabolic syndrome"; instead each component is treated to target.

1. Lifestyle modification — first and most important

• Weight loss of 7–10% of body weight over 6–12 months — the single most effective intervention; even 5% improves all components.
• Diet: calorie restriction, Mediterranean / DASH pattern, reduced refined carbohydrate and saturated/trans fat, increased fibre.
• Exercise: ≥ 150 min/week of moderate-intensity aerobic activity plus resistance training.
• Smoking cessation; alcohol moderation.

High-yield: Lifestyle modification (≥7% weight loss + ≥150 min/week exercise) is the cornerstone and first-line treatment — exam answers favour this over any drug.

2. Component-specific pharmacotherapy

Component	Drug of choice / approach
Impaired fasting glucose / prediabetes	Lifestyle first; metformin if high risk (esp. younger, obese, women with prior GDM) — DPP trial
Hypertension	ACE inhibitors / ARBs preferred (renoprotective, metabolically neutral)
High LDL / ASCVD risk	Statins (first-line for cardiovascular risk reduction)
High triglycerides (esp. > 500 mg/dL, pancreatitis risk)	Fibrates (fenofibrate); omega-3 fatty acids
Obesity (refractory)	GLP-1 receptor agonists (liraglutide, semaglutide); orlistat; bariatric surgery if BMI ≥ 37.5 (Asian) / ≥ 40, or ≥ 32.5/≥ 35 with comorbidity
Prothrombotic state	Low-dose aspirin only if established/high ASCVD risk

• Metformin is the most-favoured pharmacological agent — it reduces progression to diabetes and is the drug of choice when medication is added for dysglycaemia.
• Statins are the drug of choice to reduce the cardiovascular risk that the syndrome confers.
• GLP-1 agonists / SGLT2 inhibitors are increasingly used for combined weight, glycaemic and cardiovascular benefit.

High-yield: Best single pharmacological agent for preventing progression to diabetes = metformin; thiazolidinediones improve insulin sensitivity but are limited by weight gain, oedema and fracture risk.

Complications

• Type 2 diabetes mellitus (~5× risk) and its micro/macrovascular sequelae.
• Atherosclerotic cardiovascular disease — coronary artery disease, stroke, peripheral arterial disease (~2× risk; the dominant cause of mortality).
• NAFLD → NASH → cirrhosis / hepatocellular carcinoma.
• Chronic kidney disease and microalbuminuria.
• Obstructive sleep apnoea, hyperuricaemia/gout.
• Increased risk of PCOS-related infertility, certain malignancies, and all-cause mortality.

Key differentials

The headline NEET differential is Cushing syndrome, which shares central obesity, hypertension, glucose intolerance and dyslipidaemia but has distinguishing features.

Feature	Metabolic syndrome	Cushing syndrome
Obesity pattern	Central/visceral, generalised	Central with thin limbs, moon face, buffalo hump, supraclavicular fat pads
Striae	Absent / fine	Wide (>1 cm), purple/violaceous abdominal striae
Skin	Acanthosis nigricans, skin tags	Thin skin, easy bruising, proximal myopathy
Cortisol	Normal	Elevated, loss of diurnal rhythm; fails dexamethasone suppression
Other	—	Hypokalaemic alkalosis, osteoporosis, hirsutism, hyperpigmentation (if ACTH-dependent)

High-yield: If a vignette has central obesity plus purple striae, easy bruising, proximal muscle weakness, or hypokalaemia, think Cushing syndrome and order an overnight dexamethasone suppression test / late-night salivary cortisol, not just a lipid profile.

Other differentials/overlaps to consider: hypothyroidism (weight gain, dyslipidaemia — check TSH), PCOS (in women with hyperandrogenism), familial combined hyperlipidaemia, acromegaly (insulin resistance, hypertension), and lipodystrophy syndromes (severe insulin resistance with paradoxically low fat).

Mnemonics and named items

• Mnemonic for the 5 components — "We Better Get Healthy, Lifestyle" or simply the cluster CHAOS: Coronary risk, Hypertension, Adult-onset diabetes/insulin resistance, Obesity (central), Stroke — "metabolic syndrome = CHAOS."
• "3 of 5" rule for ATP III; "obesity + 2" for IDF.
• Eponyms: Reaven's syndrome (Gerald Reaven, Banting Lecture 1988 — described "Syndrome X"); also Kylin described the early cluster of hypertension–hyperglycaemia–hyperuricaemia in the 1920s.
• Cut-off anchors to memorise: TG 150, HDL 40/50 (M/F), BP 130/85, FPG 100; waist 90/80 for Indians, 102/88 for Western/ATP III default.

Recently asked / exam angle

• Criteria discrimination: "Which component is mandatory in IDF but not ATP III?" → Central obesity. "Which definition makes insulin resistance mandatory?" → WHO (and EGIR).
• Exact cut-offs: triglyceride ≥ 150, HDL < 40 (M)/< 50 (F), BP ≥ 130/85, FPG ≥ 100, and especially the South Asian waist cut-offs (90 cm men / 80 cm women).
• Microalbuminuria belongs to which definition? → WHO only.
• Biomarker: decreased adiponectin is characteristic; increased PAI-1 (prothrombotic).
• Best/first-line management: lifestyle modification / weight loss, with metformin as the favoured drug to prevent diabetes and statin for cardiovascular risk.
• Vignette trap: central obesity + violaceous striae + proximal weakness → Cushing syndrome, confirm with dexamethasone suppression test.
• Hepatic association: MetS is the leading cause of NAFLD/NASH; commonly linked questions on the "hepatic manifestation of insulin resistance."
• Cutaneous clue: acanthosis nigricans = marker of insulin resistance.

Rapid revision

1. Metabolic syndrome = clustering of central obesity + dyslipidaemia (high TG, low HDL) + hypertension + dysglycaemia; central mechanism is insulin resistance.
2. ATP III = any 3 of 5 components (waist optional); IDF = central obesity mandatory + any 2 others.
3. Cut-offs: TG ≥ 150, HDL < 40 (M)/< 50 (F), BP ≥ 130/85, FPG ≥ 100 mg/dL.
4. South Asian/Indian waist: men ≥ 90 cm, women ≥ 80 cm (Western/ATP III: 102/88 cm).
5. WHO criteria uniquely require insulin resistance and include microalbuminuria; uses waist–hip ratio.
6. Hallmark biomarkers: low adiponectin, high PAI-1; atherogenic lipid triad = high TG + low HDL + small dense LDL.
7. NAFLD/NASH is the hepatic manifestation; PCOS, OSA, hyperuricaemia and acanthosis nigricans are associated.
8. Risk: ~5× type 2 diabetes, ~2× cardiovascular disease/mortality.
9. Cornerstone treatment = lifestyle modification — 7–10% weight loss + ≥150 min/week exercise.
10. Drug angles: metformin to prevent diabetes, statins for ASCVD risk, ACEi/ARB for BP, fibrates for high TG.
11. Reaven's syndrome / Syndrome X = insulin resistance syndrome (Reaven, 1988).
12. Key differential = Cushing syndrome — purple striae, easy bruising, proximal myopathy, hypokalaemia → confirm with dexamethasone suppression test.